• Publications
  • Influence
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine
TLDR
The receptor-binding domain (RBD) in SARS-CoV-2 S protein was identified and it was found that the RBD protein bound strongly to human and bat angiotensin-converting enzyme 2 (ACE2) receptors and could block the binding and, hence, attachment of SARs-Cov-2 RBD and SARS -CoV RBD to ACE2-expressing cells, thus inhibiting their infection to host cells. Expand
CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells
TLDR
A novel virus entry route, CD147-spike protein, is revealed, which provides an important target for developing specific and effective drug against COVID-19. Expand
Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry
TLDR
A neutralizing monoclonal antibody, which targets the receptor-binding domain of Middle East respiratory syndrome (MERS) coronavirus spike, mediates viral entry using pseudovirus entry and biochemical assays, and results showed that MAb binds to the virus surface spike, allowing it to undergo conformational changes and become prone to proteolytic activation. Expand
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV
TLDR
This study proves the feasibility of producing cost-effective, potent, and broad-spectrum Nbs against MERS-CoV and has produced Nbs with great potentials as anti-MERS- coV therapeutics. Expand
Complement Receptor C5aR1 Inhibition Reduces Pyroptosis in hDPP4-Transgenic Mice Infected with MERS-CoV
TLDR
It is found that MERS-CoV infection induced pyroptosis and over-activation of complement in human macrophages and inflammation was suppressed by inhibiting C5aR1. Expand
A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent In Vitro, Ex Vivo, and In Vivo Antiviral Activity
TLDR
A short-lipopeptide-based fusion inhibitor, termed LP-19, is developed which mainly targets the conserved gp41 pocket site and shows highly potent inhibitory activity against HIV-1, HIV-2, and even SIV isolates. Expand
Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain
TLDR
The engineered Nbs could be developed into effective therapeutic agents for prevention and treatment of MERS-CoV infection and were very stable under extreme conditions, including low or high pH, protease, chaotropic denaturant, and high temperature. Expand
Rapid adaptation of SARS-CoV-2 in BALB/c mice: Novel mouse model for vaccine efficacy
TLDR
It is found that mouse-adapted SARS-CoV-2 at passage 6 (MACSp6) efficiently infected both aged and young wild-type BALB/c mice, resulting in moderate pneumonia as well as inflammatory responses. Expand
Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses
TLDR
The results demonstrate that E298-409 induced the highest titer of neutralizing antibodies against infection with nine ZIKV strains isolated from different hosts, countries, and time periods, and it maintained long-term anti-ZIKV immunogenicity to induceneutralizing antibodies. Expand
Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy
TLDR
The results of this study reveal that an intrinsic limitation of subunit vaccines is their artificially exposed immunodominant nonneutralizing epitopes, which can be overcome through glycan shielding. Expand
...
1
2
...